Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China

• Main Authors: Guiyuan Xiang (Author), Lingna Gu (Author), Xuan Chen (Author), Fan Wang (Author), Bohua Chen (Author), Jie Zhao (Author), Yun Lu (Author), Feng Chang (Author), Yumei Zhu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: As the first domestic PD-1 antibody approved for lung cancer in China, camrelizumab has exhibited proven effectiveness for non-small-cell lung cancer (NSCLC) patients. However, the cost-effectiveness of this new regimen remains to be investigated.Objective: To evaluate the cost-effective...